Improving Drug Development: The Strategic Value of CDMO PartnershipsMiguel Martínez-Cava2024-02-12T10:05:10+01:00February 12, 2024|Read More
The Evolution of Biopharmaceutical ManufacturingMiguel Martínez-Cava2024-01-22T08:38:03+01:00January 22, 2024|Read More
Celebrating Emmanuelle Lepine’s Legacy of Excellence at mAbxienceMiguel Martínez-Cava2024-01-15T07:54:41+01:00January 15, 2024|Read More
Boosting biologics and Contract Manufacturing at mAbxience facilitiesMiguel Martínez-Cava2023-04-03T09:26:50+02:00April 3, 2023|Read More
HK inno.N licenses in mAbxience’s denosumab biosimilarMiguel Martínez-Cava2023-01-25T10:46:18+01:00January 25, 2023|Read More
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals marketMiguel Martínez-Cava2022-08-01T17:18:20+02:00August 1, 2022|Read More
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxienceMiguel Martínez-Cava2022-04-19T22:57:54+02:00April 19, 2022|Read More
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxienceMiguel Martínez-Cava2022-05-25T23:46:17+02:00March 31, 2022|Read More
Cipla enters partnership to provide affordable oncology biosimilars to South AfricaMiguel Martínez-Cava2022-03-30T15:32:26+02:00March 30, 2022|Read More
